2-tert-butylprimaquine and Malaria--Falciparum

2-tert-butylprimaquine has been researched along with Malaria--Falciparum* in 1 studies

Other Studies

1 other study(ies) available for 2-tert-butylprimaquine and Malaria--Falciparum

Article	Year
2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8 We have recently reported that the attachment of a bulky metabolically stable tert-butyl group at the C-2 position of a quinoline ring in primaquine results in a tremendous improvement in the blood schizontocidal antimalarial activity of 8-quinolinamine. Because free heme released from hemoglobin catabolism in a malarial parasite is highly toxic, the parasite protects itself mainly by crystallization of heme into insoluble nontoxic hemozoin. We now demonstrate the ability of 2-tert-butylprimaquine to inhibit in vitro beta-hematin formation, to form a complex with heme with a stoichiometry of 1:1, and to enhance heme-induced hemolysis. The results described herein indicate that a major improvement in the blood-schizontocidal antimalarial activity of 2-tert-butylprimaquine might be due to a disturbance of heme catabolism pathway in the malarial parasite. Topics: Animals; Antimalarials; Erythrocytes; Hemeproteins; Hemolysis; Humans; Malaria, Falciparum; Parasitic Sensitivity Tests; Plasmodium falciparum; Primaquine	2007

Article

Year

2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization.

Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

We have recently reported that the attachment of a bulky metabolically stable tert-butyl group at the C-2 position of a quinoline ring in primaquine results in a tremendous improvement in the blood schizontocidal antimalarial activity of 8-quinolinamine. Because free heme released from hemoglobin catabolism in a malarial parasite is highly toxic, the parasite protects itself mainly by crystallization of heme into insoluble nontoxic hemozoin. We now demonstrate the ability of 2-tert-butylprimaquine to inhibit in vitro beta-hematin formation, to form a complex with heme with a stoichiometry of 1:1, and to enhance heme-induced hemolysis. The results described herein indicate that a major improvement in the blood-schizontocidal antimalarial activity of 2-tert-butylprimaquine might be due to a disturbance of heme catabolism pathway in the malarial parasite.

Topics: Animals; Antimalarials; Erythrocytes; Hemeproteins; Hemolysis; Humans; Malaria, Falciparum; Parasitic Sensitivity Tests; Plasmodium falciparum; Primaquine

2007